Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

Viral Infections, Non-HIV

Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study

Clin Infect Dis.

Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J

doi: 10.1093/cid/ciz633.

HIV / AIDS

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

AIDS.

Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, Uzdaviniene V, Sedlacek D, Llibre JM, Lacombe K, Nielsen LN, Florence E, Aho I, Chkhartishvili N, Szlavik J, Dragovic G, Leen C, Sambatakou H, Staub T, Laguno M, Elinav H, Tomažič J, Peters L, EuroSIDA study group.

doi: 10.1097/QAD.0000000000002570.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Lancet Infect Dis.

Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL

doi: 10.1016/

Viral Infections, Non-HIV

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Swiss Med Wkly.

Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, Müllhaupt B, Rauch A, Razavi H, Schmid P, Semela D, Stoeckle M, Negro F

doi: 10.4414/smw.2017.14543.

Viral Infections, Non-HIV

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial

Ann Intern Med.

Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers

doi: 10.7326/M17-0118.

HIV / AIDS

A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study

Clin Infect Dis.

Braun DL, Hampel B, Ledergerber B, Grube C, Nguyen H, Künzler-Heule P, Shah C, Salazar-Vizcaya L, Conen A, Flepp M, Stöckle M, Béguelin C, Schmid P, Rougemont M, Delaloye J, Bernasconi E, Nicca D, Böni J, Rauch A, Kouyos RD, Günthard HF, Fehr JS

doi: 10.1093/cid/ciaa1124.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

Hepatology.

Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S

doi: 10.1002/hep.29642.

HIV / AIDS

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

HIV Med.

Ryom L, Cotter A, De Miguel R, Béguelin C, Podlekareva D, Arribas JR, Marzolini C, Mallon P, Rauch A, Kirk O, Molina JM, Guaraldi G, Winston A, Bhagani S, Cinque P, Kowalska JD, Collins S, Battegay M, EACS Governing Board.

doi: 10.1111/hiv.12878.

HIV / AIDS

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Clin Infect Dis.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

doi: 10.1093/cid/ciy913.

Related content

Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial

A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals